Pamufetinib

DB20752InvestigationalSmall molecule

Pamufetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical... Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study).

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2 and Hepatocyte growth factor receptor
Curator reviewed
Formula / weight: C₂₇H₂₃FN₄O₄S · 518.56 g/mol (avg)
Code names: TAS-115

Resolves to

Compound

UNIIH2OL3Q4XRDCAS1190836-34-0ChEMBLCHEMBL3764045ChEBI755875PubChem44247727

Structure

InChIKeyORRNXRYWGDUDOG-UHFFFAOYSA-NSMILESCNC(=O)C1=CC2=C(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)C=CN=C2C=C1OC

Targets

P35968KDRP08581MET

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pamufetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account